New approaches to rapid onset antidepressants

Current Pharmaceutical Design

Volumn 4, Issue 4, 1998, Pages 291-302

  Briner, Karin ^a   Dodel, Richard C ^b  

^a ELI LILLY AND COMPANY   (United States)

^b INDIANA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

A 80426; ALPHA 2 ADRENERGIC RECEPTOR; AMINEPTINE; ANTIDEPRESSANT AGENT; BINOSPIRONE; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE UPTAKE INHIBITOR; FANANSERIN; FLIBANSERIN; FLUOXETINE; FLUPRAZINE; GEPIRONE; IPSAPIRONE; MIRTAZAPINE; N [2 [(8 METHYL 1,4 BENZODIOXAN 2 YLMETHYL)AMINO]ETHYL] 1 ADAMANTANECARBOXAMIDE; N [4 METHOXY 3 (4 METHYL 1 PIPERAZINYL)PHENYL] 2' METHYL 4' (5 METHYL 1,2,4 OXADIAZOL 3 YL)[1,1' BIPHENYL] 4 CARBOXAMIDE; NEFAZODONE; PAROXETINE; PINDOLOL; RECEPTOR SUBTYPE; ROXINDOLE; SEROTONIN ANTAGONIST; SEROTONIN RECEPTOR; SEROTONIN UPTAKE INHIBITOR; TANDOSPIRONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VENLAFAXINE; VILAZODONE; YM 35992;

ADRENALIN RELEASE; DEPRESSION; DRUG DESIGN; DRUG RECEPTOR BINDING; DRUG TARGETING; HUMAN; NEUROTRANSMISSION; NONHUMAN; PRIORITY JOURNAL; REVIEW; SEROTONIN UPTAKE; STRUCTURE ACTIVITY RELATION; THEORY;

ADRENERGIC ANTAGONISTS; ANTIDEPRESSIVE AGENTS; DRUG DESIGN; MOLECULAR STRUCTURE; NOREPINEPHRINE; RECEPTORS, SEROTONIN; SEROTONIN UPTAKE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP; TIME FACTORS;

EID: 0031690668     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (146)

1. Kuhn, R. Schw. Med. Wo. 1957, 87, 1135-1139.
2. Loomer, H.P.; Saunders, J.C.; Kline, N.S. Psychiatr. Res. Rep. 1958, 8, 129-141.
3. Zeelen, F.J. In Psychotropic agents. Part I: Antipsychotics and antidepressants, Hoffmeister, F.; Stille, G., Ed.; Springer-Verlag: Berlin, 1980, 351-368.
4. Kline, N.S.; Cooper, T.B. In Psychotropic agents. Part I: Antisychotics and antidepressants, Hoffmeister, F.; Stille, G., Ed.; Springer-Verlag: Berlin 1980, 369-397.
5. Pinder, R.M.; Wieringa, J.H. Med. Res. R. 1993, 13, 259-325.
6. Anderson, I.M.; Tomenson, B.M. J. Pharm. 1994, 8, 238-249.
7. Nelson, J.C. J. Clin. Psy. 1997, 58 (suppl 6), 26-31.
8. Pinder, R.M. Act. Psyc. Sc. 1997, 96, 7-13.
9. Sambunaris, A.; Hesselink, J.K.; Pinder, R.; Panagides, J.; Stahl, S.M. J. Clin. Psy. 1997, 58 (suppl 6), 40-53.
10. Broekkamp, C.L.E.; Leysen, D.; Peeters, B.W.M.M.; Pinder, R.M. J. Med. Chem. 1995, 38, 4615-4633.
11. Artigas, F. CNS Drugs 1995, 4, 79-89.
12. Goodnick, P.J. Pharmacokin. Ther. 1994, 27, 307-330.
13. Dubovsky, S.L. J. Clin. Psy. 1993, 54 (suppl), 75-83.
14. Briley, M. Hum. Psychop. 1997, 12, S121-S125.
15. Fawcett, J.; Barkin, R.L. J. Clin. Psy. 1997, 58 (suppl 6), 32-39.
16. Richelson, E. Mayo Clin. P. 1994, 69, 1069-1081.
17. Katz, M.M.; Koslow, S.H.; Maas, J.W.; Frazer, A.; Bowden, C.L.; Casper, R.; Croughan, J.; Kocsis, J.;. Redmond, E. Psychol. Med. 1987, 17, 297-309.
18. Nutt, D. Act. Psyc. Sc. 1997, 391, 31-37.
19. Potter, W.Z.; Manij, H.K. In Critical issues in the treatment of affective disorders, Langer, S.Z.; Brunello, N.; Racagni, G.; Mendlewicz, J., Ed.; S. Karger: Basel, 1994, 118-126.
20. Anonymous. Eur. Neurops. 1995, 5, 151-155.
21. Quitkin, F.M.; Rabkin, J.G.; Markovitz, J.M.; Stewart, J.W.; McGrath, P.J.; Harrison, W. Arch. G. Psyc. 1987, 44, 259-264.
22. Blier, P.; de Montigny, C.; Chaput, Y. J. Clin. Psy. 1990, 51 (suppl), 14-20.
23. Artigas, F. Trends Phar. 1993, 14, 262.
24. Frazer, A.; Scott, P.A. In Critical issues in the treatment of affective disorders, Langer, S.Z.; Brunello, N.; Racagni, C.; Mendlewicz, J., Ed.; Karger: Basel, 1994, 8289.
25. Sackeim, H.A.; Devanard, D.P.; Nobler, M.S. In Psychopharmacology: the fourth generation of progress, Bloom, F.E.; Kupfer, D.J., Ed.; Raven: New York 1995, 1123-1141.
26. Wu, J.C.; Bunney, W.E. Am. J. Psychi. 1990, 147, 14-21.
27. Heninger, G.R.; Delgado, P.L.; Charney, D.S. Pharmacopsy. 1996, 29, 2-11.
28. Borsini, F.; Cesana, R.; Kelly, J.; Leonard, B.E.; McNamara, M.; Richards, J.; Seiden, L. Psychophar. 1997, 134, 378-386.
29. Freeman, H. Int. Clin. Ps. 1997, 12 (suppl 3), S29-S33.
30. Derivan, A.; Entsuah, R.A.; Kikta, D. Psychoph. B. 1995, 31, 439-447.
31. Montgomery, S.A. Int. Clin. Ps. 1997, 12 (suppl 3), S1-S5.
32. Stassen, H.H.; Angst, J.; Delini-Stula, A. Eur. Psy. 1994, 9, 129-136.
33. Quitkin, F.M.; McGrath, P.J.; Stewart, J.W.; Taylor, B.P.; Klein, D.T. Neuropsych. 1996, 15, 390-394.
34. Montgomery, S.A. Psychoph. B. 1995, 31, 41-44.
35. Prien, R.F.; Blaine, J.D.; Levin, J. Hosp. Comm. Psychi. 1985, 36, 513-516.
36. Katz, M.M.; Koslow, S.H.; Frazer, A. Depr. Anxiety 1997, 4, 257-267.
37. Derivan, A.T. Psychoph. B. 1995, 31, 23-28.
38. Hieble, J.P.; Ruffolo, R.R. Ann. N. Y. Ac. Sc. 1995, 763, 8-21.
39. Roth, B.L.; Hyde, E.G. Handb. Exp. Phar. 1997, 129, 367-394.
40. Hoeltje, H.-D. Pract. Med. Chem. 1996, 126, 437-457.
41. Deakin, J.F.; Graeff, F.G.; Guimaraes, F.S. Trends Phar. 1993, 14, 263.
42. De Vry, J. Psychophar. 1995, 121, 1-26.
43. Scuvee-Moreau, J.; Dresse, A. Eur. J. Pharm. 1979, 57, 219-225.
44. Hjorth, S.; Auerbach, S.B. Beh. Brain Res. 1996, 73, 281-283.
45. Gartside, S.E.; Umbers, V.; Hajos, M.; Sharp, T. Br. J. Ph. 1995, 115, 1064-1070.
46. Romero, L.; Celada, P.; Artigas, F. Eur. J. Pharm. 1994, 265, 103-106.
47. (a) Romero, L.; Bel, N.; Artigas, F.; De Montigny, C.; Blier, P. Neuropsych. 1996, 15, 349-360.
48. (b) Clifford, E.M.; Gartside, S.E.; Umbers, V.; Cowen, P.J.; Hajos, M.; Sharp, T. Br. J. Pharmacol. 1998, 124, 206-212.
49. Artigas, F.; Romero, L. Soc. Neurosci. Abstracts 1996, 22, 611.
50. Arborelius, L.; Nomikos, G.G.; Hertel, P.; Salmi, P.; Grillner, P.; Hook, B.B.; Hacksell, U.; Svensson, T.H. N.-S. Arch. Ph. 1996, 353, 630-640.
51. Tome, M.B.; Isaac, M.T.; Harte, R.; Holland, C. Int. Clin. Ps. 1997, 12, 81-89.
52. Perez, V.; Gilaberte, I.; Faries, D.; Alvarez, E.; Artigas, F. Lancet 1997, 349, 1594-1597.
53. Bailly, D. CNS Drugs 1996, 5, 115-136.
54. Avron, J.; Everitt, D.E.; Weiss, D. J. Am, Med. A. 1986, 255, 357-360.
55. Artigas, F.; Romero, L.; Montigny, C.; Blier, P. Trends Neur. 1996, 19, 378-383.
56. Blier, P.; Bergeron, R.; de Montigny, C. Neuropsych. 1997, 16, 333-338.
57. Rasmussen, K.; Rocco, V.P. Ann. Rep. Med. Chem. 1995, 30, 1-9.
58. Routledge, C. Beh. Brain R. 1996, 73, 153-156.
59. Romero, L.; Casanovas, J.M.; Hervas, I.; Cortes, R.; Artigas, F. In Antidepressants. New pharmacological strategies, Skolnick, P., Ed.; Humana Press: Totowa 1997, 1-33.
60. Blier, P.; de Montigny, C. J. Clin. Psy. 1990, 10 (suppl 3), 13-20.
61. Boddeke, H.W.G.M.; Fragin, A.; Raymond, J.R.; Schoeffter, P.; Hoyer, D. N. -S. Arch. Ph. 1992, 345, 257-263.
62. Meller, E.; Goldstein, M.; Bohmaker, K. Molec. Pharm. 1990, 216, 373-378.
63. Price, G.W.; Roberts, C.; Watson, J.; Buiton, M.; Mulholland, K.; Middlemiss, D.N.; Jones, B.J. Beh. Brain R. 1996, 73, 79-82.
64. Millan, M.J.; Rivet, J.M.; Canton, H.; Lejeune, F.; Bervoets, K.; Brocco, M.; Gobert, A.; Lefebvre de Ladonchamps, B.; Le Marouille-Girardon, S.; Verriele, L.; Laubie, M.; Laviclle, G. J. Pharm. Exp. 1992, 262, 451-63.
65. Bartoszyk, G.D.; Hegenbart, R.; Ziegler, H. Eur. J. Pharm. 1997, 322, 147-153.
66. Pinder, R.M. In Emerging Drugs: The prospect for improved medicines, Bowman, W.C.; Fitzgerald, J.D.; Taylor, J.B., Ed.: Ashley Publications Ltd.: London, 1996, 177-193.
67. Dumuis, A.; Sebben, M.; Bockaert, J. Mol. Pharm. 1988, 33, 178-186.
68. Yevich, J.P.; Eison, M.S.; Eison, A.S.; Taylor, D.P.; Yocca, F.D.; VanderMaelen, C.P.; Riblet, L.A.; Robinson, D.S.; Roberts, D.L.; Temple, D.L. Prog. Clin. Biol. Res. 1990, 361, 443-51.
69. Seymour, P.A.; Mena, E.E.; McLean, S.; Heym, J. Prog. Clin. Biol. Res. 1990, 361, 453-460.
70. Funck-Brentano, C. Am. J. Med. Sc. 1989, 297, 49-52.
71. Schipper, J.; Tulp, M.T.M.; Berkelmans, B.; Mos, J.; Van der Heijden, J.A.M.; Olivier, B. Hum. Psychop. 1991, 6 (suppl), S53-S61.
72. Grof, P.; Joffe, R.; Kennedy, S.; Persad, E.; Syrotiuk, J.; Bradford, D. Int. Clin. Ps. 1993, 8, 167-172.
73. Ansseau, M.; Pitchot, W.; Moreno, A.G.; Wauthy, J.; Papart, P. Hum. Psychop. 1993, 8, 279.
74. Kidd, E.J.; Haj-Dahmane, S.; Jolas, T.; Lanfumey, L.; Fattaccini, C.M.; GuardiolaLemaitre, B.; Gozlan, H.; Hamon, M. J. Pharm. Exp. 1993, 264, 863-872.
75. Podona, T.; Guardiola-Lemaitre, B.; Caignard, D.H.; Adam, G.; Pfeiffer, B.; Renard, P.; Guillaumet, G. J. Med. Chem. 1994, 37, 1779-93.
76. Borsini, F. Pharm. Res. 1994, 30, 1-11.
77. Mongeau, R.; Blier, P.; de Montigny, C. Brain Res. R. 1997, 23, 145-195.
78. Borsini, F.; Giraldo, E.; Monferini, E.; Antonini, G.; Parenti, M.; Bietti, G.; Donetti, A. N.-S. Arch. Ph. 1995, 352, 276-82.
79. D'Aquila, P.; Monleon, S.; Borsini, F.; Brain, P.; Willner, P. Eur. J. Pharm. 1997, 340, 121-132.
80. Uchida, H.; Inagawa, K.; Tameda, C.; Miyauchi, T. Prog. Neur. P. 1995, 19, 1201-1216.
81. Moser, P.C.; Tricklebank, M.D.; Middlemiss, D.N.; Mir, A.K.; Hibert, M.F.; Fozard, J.R. Br. J. Ph. 1990, 99, 343-349.
82. Hartig, P.R.; Hoyer, D.; Humphrey, P.P.; Martin, G.R. Trends Phar. 1996, 17, 103-105.
83. Halazy, S.; Perez, M.; Fourrier, C.; Pallard, I.; Pauwels, P.J.; Palinier, C.; John, G.W.; Valentin, J.P.; Bonnafous, R.; Martinez, J. J. Med. Chem. 1996, 39, 4920-4927.
84. Blier, P.; Galzin, A.-M.; Langer, S.Z. J. Pharm. Exp. 1990, 254, 236-244.
85. Galzin, A.M.; Poirier, M.F.; Lista, A.; Chodkiewicz, J.P.; Blier, P.; Ramdine, R.; Loo, H.; Roux, F.X.; Redondo, A.; Langer, S.Z. J. Neurochem. 1992, 59, 1293-1301.
86. Pauwels, P.J. Gen. Pharm. 1997, 29, 293-303.
87. Oksenberg, D. Nature (London) 1992, 360, 161-163.
88. Metcalf, M.A.; Mc Guffin, R.W.; Hamblin, M.W. Biochem. Pharmacol. 1992, 44, 1917-1920.
89. Clitherow, J.W.; Scopes, D.I.; Skingle, M.; Jordan, C.C.; Feniuk, W.; Campbell, I.B.; Carter, M.C.; Collington, E.W.; Connor, H.E.; Higgins, G.A.; Beattie, D.; Kelly, H.A.; Mitchell, W.L.; Oxford, A.W.; Wadsworth, A.H.; Tyers, M.B. J. Med. Chem. 1994, 37, 2253-2257.
90. Lamothe, M.; Pauwels, P.J.; Belliard, K.; Schambel, P.; Halazy, S. J. Med. Chem. 1997, 40, 3542-50.
91. Jorand-Lebrun, C.; Pauwels, P.J.; Palmier, C.; Moret, C.; Chopin, P.; Perez, M.; Marien, M.; Halazy, S. J. Med. Chem. 1997, 40, 3974-3978.
92. Taylor, D.P.; Carter, R.B.; Eison, A.S.; Mullins, U.L.; Smith, H.L., Torrente, J.R.; Wright, R.N.; Yocca, F.D. J. Clin. Psy. 1995, 56 (suppl 6), 3-11.
93. (a) Ellingrod, V.L.; Perry, P.J. Am. J. Heal. 1995, 52, 2799-2812.
94. (b) Feighner, J.; Targum, S.D.; Bennett, M.E.; Roberts, D.L.; Kensler, T.T.; D'Amico, M.F.; Hardy, S.A. J. Clin. Psychiatry 1998, 59, 246-253.
95. Cusack, B.; Nelson, A.; Richelson, E. Psychophar. 1994, 114, 559-565.
96. Mokrosz, J.L.; Duszynska, B.; Paluchowska, M.H.; Charakchieva-Minol, S.; Mokrosz, M.J. Arch. Pharm. 1995, 328, 623-625.
97. Mellow, A.M.; Lawler, B.A.; Sunderland, T.; Mueller, E.A.; Molchan, S.E.; Murphy, D.L. Biol. Psychi. 1990, 28, 588-594.
98. Berendsen, H.H.; Broekkamp, C.L. Eur. J. Pharm. 1994, 253, 83-89.
99. Malleron, J.-L.; Guérémy, C.; Mignani, S.; Peyronel, J.-F.; Truchon, A.; Blanchard, J.-C.; Doble, A.; Laduron, P.; Piot, O.; Zundel, J.-L.; Betschart, J.; Canard, H.; Chaillou, P.; Ferris, O.; Huon, C.; Just, B.; Kerphirique, R.; Martin, B.; Mouton, P.; Renaudon, A. J. Med. Chem. 1993, 36, 1194-1202.
100. Hatanaka, K.; Nomura, T.; Hikada, K.; Takeuchi, H.; Yatsugi, S.; Fujii, M.; Yamaguchi, T. Neuropharm. 1996, 35, 1621-1626.
101. Rickels, K.; Derivan, A.; Entsuah, R.; Miska, S.; Rudolph, R. Depression 1995, 3, 146-153.
102. Frazer, A. J. Clin. Ps. 1997, 58, 9-25.
103. Yardley, J.P.; Husbands, G.E.; Stack, G.; Butch, J.; Bicksler, J.; Moyer, J.A.; Muth, E.A.; Andree, T.; Fletcher, H.d.; James, M.N.; Sielecki, A.R. J. Med. Chem. 1990, 33, 2899-2905.
104. Muth, E.A.; Moyer, J.A.; Haskins, J.T.; Andree, T.H.; Husbands, G.E.M. Drug Dev. R. 1991, 23, 191.
105. Moret, C.; Charveron, M.; Finberg, J.P.; Conzinier, J.P.; Briley, M. Neuropharm. 1985, 24, 1211-1219.
106. Bonnaud, B. J. Med. Chem. 1987, 30, 318-325.
107. Wong, D.T.; Bymaster, F.P.; Mayle, D.A.; Reid, L.R.; Krushinski, J.H.; Robertson, D.W. Neuropsych. 1993, 8, 23-33.
108. Fuller, R.W.; Wong, D.T.; Robertson, D.W. Med. Res. R. 1992, 11, 17-34.
109. Meyer, M.D.; Hancock, A.A.; Tietje, K.; Sippy, K.B.; Prasad, R.; Stout, D.M.; Arendsen, D.L.; Donner, G.B.; Carroll, W.A. J. Med. Chem. 1997, 40, 1049-1062.
110. Meyer, M.D.; Hancock, A.A.; Tietje, K.; Sippy, K.B.; Giardina, W.J.; Kerwin, J.F. Bioorg. Med. 1995, 5, 2287-2292.
111. Hancock, A.A.; Buckner, S.A.; Giardina W.J.; Brune M.E.; Lee J.Y.; Morse P.A.; Oheim K.W.; Stanisic D.S.; Warner R.B.; Kerkman D.J.; DeBernardis, J.F. J. Pharm. Exp. 1995, 272, 1160-1169.
112. Giardina, W.J.; Buckner, S.A.; Brune, M.E.; Hancock, A.A.; Wismer, C.T.; Milicic, I.; Rattin, A.J.; Roux, S.; Wettstein, J.G.; Meyer, M.D.; Porsolt, R.D.; Kerwin, J.F.; Williams, M. Drug Dev. R. 1995, 35, 246-260.
113. Zelle, R.E.; Hancock, A.A.; Buckner, S.A.; Basha, F.Z.; Tietje, K.; DeBernardis, J.F.; Meyer, M.M. Bioorg. Med. 1994, 4, 1319-1322.
114. Sramek, J.J.; Kashkin, K.; Jasinsky, O.; Kardatzke, D.; Kennedy, S.; Cutler, N.R. Depression 1995, 3, 199-203.
115. Nutt, D.J.; Pinder, R.M. J. Psychoph. 1996, 10, 35-42.
116. Preskorn, S.H. J. Clin. Psy. 1997, 58 (supp 6), 3-8.
117. de Boer, T.H.; Nefkens, F.; van Helvoirt, A.; van Delft, A.M. J. Pharm. Exp. 1996, 277, 852-60.
118. Missale, C.; Nash, S.R.; Robinson, S.W.; Jaber, M.; Caron, M.G. Phys. Rev. 1998, 78, 189-225.
119. Willner, P. In Psychoactive drugs: tolerance and sensitization, Emmett-Oglesby, M.W.; Goudie, A.J., Ed.; Humana Press: New Jersey 1989, 407-459.
120. Klimek, V.; Maj, J. J. Pharm. Phar. 1989, 41, 555-558.
121. Willner, P. Int. Clin. Psy. 1997, 12 (suppl 3), S7-S14.
122. Sampson, D.; Willner, P.; Muscat, R. Psychophar. 1991, 104, 491-495.
123. Brown, A.S.; Gershon, S. J. Neur. Tr. 1993, 91, 75-109.
124. Maj, J.; Rogoz, Z.; Skuza, G.; Kolodziejczyk, K. J. Neur. Tr. 1997, 104, 525-533.
125. Eden, R.J.; Costall, B.; Domeney, A.M.; Gerrard, P.A.; Harvey, C.A.; Kelly, M.E.; Naylor, R.J.; Owen, D.A.; Wright, A. Pharm. Bio. B. 1991, 38, 147-154.
126. Grunder, G.; Wetzel, H.; Hammes, E.; Benkert, O. Psychophar. 1993, 111, 123-126.
127. Benkert, O.; Brunder, G.; Wetzel, H. Pharmacops. 1992, 25, 254-260.
128. Deniker, P.; Besancon, G.; Colonna, L.; Coudert, A.J.; Danion, J.M.; Dufour, H.; Escande, M.; Feline, A.; Fontan, M.; Gayral, L.F.; et al. Encephale 1982, 8, 355-370.
129. Dalery, J.; Rochat, C.; Peyron, E.; Bernard, G. Encephale 1992, 18, 257-262.
130. Seyfried, C.A.; Greiner, H.E.; Haase, A.F. Eur. J. Pharm. 1989, 160, 31-41.
131. Mitchell, P.B. Psychoph. B. 1995, 31, 509-519.
132. Latini, S.; Pazzagli, M.; Pepeu, G.; Pedata, F. Gen. Pharm. 1996, 27, 925-933.
133. Sarges, R.; Howard, H.R.; Browne, R.G.; Lebel, L.A.; Seymour, P.A.; Koe, B.K.; J. Med. Chem. 1990, 33, 2240-2254.
134. Leonard, B.E. In Antidepressants, Skolnick, P., Ed.; Humana Press: Totowa, 1997, 159-172.
135. Bittiger, H.; Froestl, W.; Mickel, S.J.; Olpe, H.-R. Trends Phar. 1993, 14, 391-394.
136. Johnson, G.; Omstein, P.L. Curr. Pharm. Des. 1996, 2, 331-356.
137. Kirkegaard, C.; Faber, J. Eur. J. Endoc. 1998, 138, 1-9.
138. Nemeroff, C.B. Mol. Psychi. 1996, 1, 336-342.
139. Holsboer, F.; Barden, N. Endocr. Rev. 1996, 17, 187-205.
140. Prange, A.J., Jr. Thyroid 1996, 6, 537-543.
141. Prange, A.J., Jr.; Lara, P.P.; Wilson, I.C.; Alltop, L.B.; Breese, G.R. Lancet 1972, 2, 999-1002.
142. Ozawa, H.; Rasenick, M.M. J. Neurochem. 1991, 56, 330-338.
143. Nestler, E., J,; Duman, R., S, In Psychopharmacology: The fourth generation of progress, Bloom, F.E.; Kupfer, D.J., Ed.; Raven-Press: New York 1995, 695-704.
144. Baron, M. Psych. Gen. 1997, 7, 49-51.
145. Nibuya, M.; Morinobu, S.; Duman, R.S. J. Neurosc. 1995, 15, 7539-7547.
146. Paul, S.M.; Wu, X.; Liang, Y.; Ginns, I. In Antidepressants, Skolnick, P., Ed.; Humana Press: Totowa, 1997, 235-250.